Evidence map›Paper›PMID 29405351›Full record

ArticleAnnals of neurology2018

Predicting clinical diagnosis in Huntington's disease: An imaging polymarker.

Sarah L Mason, Richard E Daws, Eyal Soreq, Eileanoir B Johnson, Rachael I Scahill, Sarah J Tabrizi, Roger A Barker, Adam Hampshire

Abstract read
In one paragraph

Article in Annals of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sarah L MasonJohn Van Geest Centre for Brain Repair, University of Cambridge, United Kingdom.
Richard E DawsThe Computational, Cognitive & Clinical Neuroimaging Laboratory (CNL), Division of Brain Sciences, Imperial College London, United Kingdom.
Eyal SoreqThe Computational, Cognitive & Clinical Neuroimaging Laboratory (CNL), Division of Brain Sciences, Imperial College London, United Kingdom.
Eileanoir B JohnsonHuntington's Disease Research Centre, UCL Institute of Neurology, University College London, United Kingdom.
Rachael I ScahillHuntington's Disease Research Centre, UCL Institute of Neurology, University College London, United Kingdom.
Sarah J TabriziHuntington's Disease Research Centre, UCL Institute of Neurology, University College London, United Kingdom.
Roger A BarkerJohn Van Geest Centre for Brain Repair, University of Cambridge, United Kingdom.
Adam HampshireThe Computational, Cognitive & Clinical Neuroimaging Laboratory (CNL), Division of Brain Sciences, Imperial College London, United Kingdom.

Funding

Department of HealthWellcome Trust 200181/Z/15/Z
6 · The paper itself

Abstract

objectiveHuntington's disease (HD) gene carriers can be identified before clinical diagnosis; however, statistical models for predicting when overt motor symptoms will manifest are too imprecise to be useful at the level of the individual. Perfecting this prediction is integral to the search for disease modifying therapies. This study aimed to identify an imaging marker capable of reliably predicting real-life clinical diagnosis in HD.

methodA multivariate machine learning approach was applied to resting-state and structural magnetic resonance imaging scans from 19 premanifest HD gene carriers (preHD, 8 of whom developed clinical disease in the 5 years postscanning) and 21 healthy controls. A classification model was developed using cross-group comparisons between preHD and controls, and within the preHD group in relation to "estimated" and "actual" proximity to disease onset. Imaging measures were modeled individually, and combined, and permutation modeling robustly tested classification accuracy.

resultsClassification performance for preHDs versus controls was greatest when all measures were combined. The resulting polymarker predicted converters with high accuracy, including those who were not expected to manifest in that time scale based on the currently adopted statistical models.

interpretationWe propose that a holistic multivariate machine learning treatment of brain abnormalities in the premanifest phase can be used to accurately identify those patients within 5 years of developing motor features of HD, with implications for prognostication and preclinical trials. Ann Neurol 2018;83:532-543.

Indexed as

AdultAgedCohort StudiesFemaleHumansHuntington DiseaseMagnetic Resonance ImagingMaleMiddle AgedPredictive Value of Tests

Identifiers

PMID29405351
PMCPMC5900832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.